SFI
BLRX

Susquehanna Fundamental Investments’s BioLineRX BLRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-476
Closed -$52K – 1453
2021
Q3 		$52K Hold
476
– – ﹤0.01% 1660
2021
Q2 		$53K Sell
476
-1,390
-74% -$163K ﹤0.01% 1618
2021
Q1 		$208K Buy
1,866
+840
+82% +$101K ﹤0.01% 1384
2020
Q4 		$103K Buy
+1,026
New +$89.7K ﹤0.01% 1425

Other funds holding BLRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Susquehanna Fundamental Investments's BLRX Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of BioLineRX (BLRX) in Q4 2021, closing a stake of 476 shares — an estimated $52K sold.

Susquehanna Fundamental Investments first reported a position in BLRX in Q4 2020 and held it in 4 quarters. The position peaked at $208K in Q1 2021. 30 funds tracked by Wall St. Rank hold BLRX as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining BioLineRX position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 476 BioLineRX shares in Q4 2021, an estimated $52K.
  • Susquehanna Fundamental Investments first reported a position in BioLineRX in Q4 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's BioLineRX position peaked at $208K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held BioLineRX as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.